Efficacy of Oral Labetalol Versus Nifedipine for the management of Severe Hypertension in Pregnancy: A Randomized Controlled Trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202406618856160

Enrollment

176

Registered

2024-06-28

Start date

2022-10-04

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Cardiology

Interventions

Nifedipine

Labetalol

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Pregnant women aged 18 years and above. Pregnancy with fetus at gestational age of 28 weeks and above. Women that require pharmacological blood pressure control for severe hypertension. Pregnant women who can willingly ingest oral medications. They consented to the study.

Exclusion criteria

Exclusion criteria: Women who are unwilling or unable to give consent. Women who are actively wheezing or asthmatic Known heart disease patients. Diabetes mellitus. Symptoms and Signs suggestive of heart disease

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of oral labetalol versus nifedipine retard in the optimal control of blood pressure (BP) in women with severe hypertension in pregnancy at Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife.	—

Secondary

Measure	Time frame
To determine and compare the mean blood pressure control, number of hours to achieve optimal control of BP and/or need for use of additional drugs, the effect of coadministration of both classes of oral antihypertensives in recalcitrant cases and the adverse outcomes experienced in each group.	—

Countries

Nigeria

Contacts

Public ContactAkintunde Fehintola

Supervisor 2

fehintolaakintunde@gmail.com+23408037998247

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026